550 related articles for article (PubMed ID: 15022321)
1. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
3. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
5. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis.
Mirosavljevic D; Quinn JM; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
J Bone Miner Res; 2003 Jun; 18(6):984-93. PubMed ID: 12817750
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
[TBL] [Abstract][Full Text] [Related]
8. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
Yamaguchi M; Uchiyama S
Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
[TBL] [Abstract][Full Text] [Related]
10. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
13. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
14. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
Wattel A; Kamel S; Prouillet C; Petit JP; Lorget F; Offord E; Brazier M
J Cell Biochem; 2004 May; 92(2):285-95. PubMed ID: 15108355
[TBL] [Abstract][Full Text] [Related]
15. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
18. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bone destruction and osteoimmunology.
Takayanagi H
J Periodontal Res; 2005 Aug; 40(4):287-93. PubMed ID: 15966905
[TBL] [Abstract][Full Text] [Related]
20. Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.
Iwamoto K; Miyamoto T; Sawatani Y; Hosogane N; Hamaguchi I; Takami M; Nomiyama K; Takagi K; Suda T
Biochem Biophys Res Commun; 2004 Dec; 325(1):229-34. PubMed ID: 15522223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]